DAFTAR PUSTAKA

1. Mendis S, Puska P, Norrving B, World Health Organization., World Heart

Federation., World Stroke Organization. Global atlas on cardiovascular disease
prevention and control. Geneva: World Health Organization; 2011. vi, 155 p.
p.
2. Yudiarto F, Machfoed M, Darwin A, Ong A, Karyana M, Siswanto. Indonesia
Stroke Registry (S12.003). Neurology. 2014;82(10 Supplement):S12.003.
3. Lamsudin R WS, Nuradyo D, Sutarni S. Stroke Profile in Yogyakarta:
Morbidity, Mortality, and Risk Factor of Stroke. BKM. 1998;Suppl
XIV(Recent Management of Stroke):53-69.
4. Setyopranoto I. Stroke: Gejala dan penatalaksanaan. Cermin Dunia Kedokteran.
2011;38(4):247.
5. Misbach J, Wendra A. Clinical pattern of hospitalized strokes in 28 hospitals
in Indonesia. Medical Journal of Indonesia. 2000;9(1):29-34.
6. Arofah AN. PENATALAKSANAAN STROKE TROMBOTIK: Peluang
Peningkatan Prognosis Pasien. Jurnal Saintika Medika. 2012;7(14).
7. Nurazam M. Analysis of The Time to Hospital Admission for Stroke Patient in
dr Sardjito Hospital from 2011-2013 [Undergraduate Thesis]. Yogyakarta:
Gadjah Mada University; 2014.
8. Muhibbi S. Jumlah Leukosit Sebagai Indikator Keluaran Stroke Iskemik
[Masters Thesis]. Semarang (Indonesia): Universitas Diponegoro; 2004.
9. Dongoran R. Jumlah Neutrofil Absolut sebagai Indikator Keluaran Stroke
Iskemik [Master Thesis]. Semarang (Indonesia): Universitas Diponegoro; 2007.
10. Elkind MSV, Cheng J, Rundek T, Boden-Albala B, Sacco RL. Leukocyte count
predicts outcome after ischemic stroke: The Northern Manhattan Stroke Study.
Journal of Stroke and Cerebrovascular Diseases. 2004;13(5):220-7.
11. Nardi K, Milia P, Eusebi P, Paciaroni M, Caso V, Agnelli G. Admission
Leukocytosis in Acute Cerebral Ischemia: Influence on Early Outcome.
Journal of Stroke and Cerebrovascular Diseases. 2011;21(8):819-24.

38
 39

12. Nomura E, Naka H, Wakabayashi S, Kajikawa H, Matsumoto M. Leukocytes

May Have 2 Opposing Effects in Intravenous rtPA Treatment for Ischemic
Stroke. Clinical and Applied Thrombosis/Hemostasis.
2012:1076029612452115.
13. Tiainen M, Meretoja A, Strbian D, Suvanto J, Curtze S, Lindsberg PJ, et al.
Body temperature, blood infection parameters, and outcome of thrombolysis-
treated ischemic stroke patients. International Journal of Stroke.
2013;8(8):632-8.
14. Furlan JC, Vergouwen MDI, Fang J, Silver FL. White blood cell count is an
independent predictor of outcomes after acute ischaemic stroke. European
Journal of Neurology. 2014;21(2):215-22.
15. Heikinheimo T, Putaala J, Haapaniemi E, Kaste M, Tatlisumak T. Leucocyte
count in young adults with first-ever ischaemic stroke: associated factors and
association on prognosis. International Journal of Stroke. 2015;10(2):245-50.
16. Lipton P. Ischemic cell death in brain neurons. Physiological reviews.
1999;79(4):1431-568.
17. Moskowitz MA, Lo EH, Iadecola C. The Science of Stroke: Mechanisms in
Search of Treatments. Neuron. 2010;67(2):181-98.
18. Jablonska AL, B. Stroke induced brain changes: implications for stem cell
transplantation. Acta Neurobiologiae Experimentalis. 2011.;71(1):74-85.
19. Majid A. Neuroprotection in Stroke: Past, Present, and Future. ISRN
Neurology. 2014;2014:17.
20. Manev H, Favaron M, Guidotti A, Costa E. Delayed increase of Ca2+ influx
elicited by glutamate: role in neuronal death. Molecular pharmacology.
1989;36(1):106-12.
21. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to
translation. Nature medicine. 2011;17(7):796-808.
22. Yilmaz G, Granger DN. Leukocyte recruitment and ischemic brain injury.
Neuromolecular medicine. 2010;12(2):193-204.
 40

23. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid

barriers: function and dysfunction. Seminars in immunopathology.
2009;31(4):497-511.
24. Xu X, Jiang Y. The Yin and Yang of Innate Immunity in Stroke. BioMed
Research International. 2014;2014:8.
25. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of
inflammatory cells. Journal of leukocyte biology. 2010;87(5):779-89.
26. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, et al.
Down-regulation of the macrophage lineage through interaction with OX2
(CD200). Science (New York, NY). 2000;290(5497):1768-71.
27. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et
al. Control of microglial neurotoxicity by the fractalkine receptor. Nature
neuroscience. 2006;9(7):917-24.
28. Taylor RA, Sansing LH. Microglial responses after ischemic stroke and
intracerebral hemorrhage. Clinical and Developmental Immunology.
2013;2013.
29. Li TP, S; Yu, Y; Wu, X; Guo, J; Zhang, S Proliferation of parenchymal
microglia is the main source of microgliosis after ischaemic stroke. Brain: A
Journal of Neurology. 2013;136(12):3578-88.
30. Chiba T, Umegaki K. Pivotal roles of monocytes/macrophages in stroke.
Mediators of inflammation. 2013;2013.
31. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe C-U, Siler DA, et
al. Temporal and spatial dynamics of cerebral immune cell accumulation in
stroke. Stroke. 2009;40(5):1849-57.
32. Kostulas N, Li H-L, Xiao B-G, Huang Y-M, Kostulas V, Link H. Dendritic
cells are present in ischemic brain after permanent middle cerebral artery
occlusion in the rat. Stroke. 2002;33(4):1129-34.
33. Becker KJ, Kalil AJ, Tanzi P, Zierath DK, Savos AV, Gee JM, et al.
Autoimmune Responses to the Brain After Stroke Are Associated With Worse
Outcome. Stroke. 2011;42(10):2763-9.
 41

34. Shibata D, Cain K, Tanzi P, Zierath D, Becker K. Myelin basic protein

autoantibodies, white matter disease and stroke outcome. Journal of
Neuroimmunology. 2012;252(1):106-12.
35. Rocklin RE, Sheremata WA, Feldman RG, Kies MW, David JR. The Guillain-
Barrù Syndrome and Multiple Sclerosis. New England Journal of Medicine.
1971;284(15):803-8.
36. Baird AE, Dambrosia J, Janket S, Eichbaum Q, Chaves C, Silver B, et al. A
three-item scale for the early prediction of stroke recovery. Lancet.
2001;357(9274):2095-9.
37. National Institute of Health Stroke Scale form. Available from:
http://www.ninds.nih.gov/doctors/nih_stroke_scale.pdf.
38. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system
injury-induced immune deficiency syndrome. Nature reviews Neuroscience.
2005;6(10):775-86.
39. Adams HP, Olinger CP, Marler JR, Biller J, Brott TG, Barsan WG, et al.
Comparison of admission serum glucose concentration with neurologic
outcome in acute cerebral infarction. A study in patients given naloxone. Stroke.
1988;19(4):455-8.
40. Young B, Ott L, Dempsey R, Haack D, Tibbs P. Relationship between
admission hyperglycemia and neurologic outcome of severely brain-injured
patients. Annals of Surgery. 1989;210(4):466-73.
41. Nardi K, Milia P, Eusebi P, Paciaroni M, Caso V, Agnelli G. Predictive value
of admission blood glucose level on short-term mortality in acute cerebral
ischemia. Journal of Diabetes and Its Complications. 2012;26(2):70-6.
42. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent
predictor of poor outcome after acute stroke? Results of a long-term follow up
study. BMJ : British Medical Journal. 1997;314(7090):1303-6.
43. Bruno A, Biller J, Adams HP, Jr., Clarke WR, Woolson RF, Williams LS, et
al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG
10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology.
1999;52(2):280-4.
 42

44. Uyttenboogaart M, Koch MW, Stewart RE, Vroomen PC, Luijckx GJ, De
Keyser J. Moderate hyperglycaemia is associated with favourable outcome in
acute lacunar stroke. Brain : a journal of neurology. 2007;130(Pt 6):1626-30.
45. Badiger SA, PT; Narone, U. Hyperglycemia and Stroke. International Journal
of Stroke Research. 2013;1(1):1-6.
46. Thaib P. Hubungan antara kadar LDL darah pada stroke iskemik fase akut
dengan lama perawatan pasien pulang hidup dan pulang meninggal
[Undergraduate Thesis]. Semarang [Indonesia]: Diponegoro University; 2008.
47. Kim E, Tolhurst AT, Qin LY, Chen XY, Febbraio M, Cho S. CD36/fatty acid
translocase, an inflammatory mediator, is involved in hyperlipidemia-induced
exacerbation in ischemic brain injury. The Journal of neuroscience : the official
journal of the Society for Neuroscience. 2008;28(18):4661-70.
48. Putaala J, Strbian D, Mustanoja S, Haapaniemi E, Kaste M, Tatlisumak T.
Functional outcome in young adult ischemic stroke: impact of lipoproteins.
Acta Neurologica Scandinavica. 2013;127(1):61-9.
49. Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J. Better
outcome after stroke with higher serum cholesterol levels. Neurology.
2000;54(10):1944-9.
50. Roquer J, Cuadrado-Godia E, Rodríguez-Campello A, Jiménez-Conde J,
Martínez-Rodríguez JE, Giralt E, et al. Serum cholesterol levels and survival
after rtPA treatment in acute stroke. European Journal of Neurology.
2012;19(4):648-54.
51. Pikija S, Trkulja V, Juvan L, Ivanec M, Dukši D. Higher on-admission serum
triglycerides predict less severe disability and lower all-cause mortality after
acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases.
2013;22(7):e15-e24.
52. Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PAG, Group ftIC. Blood
Pressure and Clinical Outcomes in the International Stroke Trial. Stroke.
2002;33(5):1315-20.
 43

53. Willmot M, Leonardi-Bee J, Bath PMW. High Blood Pressure in Acute Stroke
and Subsequent Outcome: A Systematic Review. Hypertension.
2004;43(1):18-24.
54. Qureshi AI. Acute Hypertensive Response in Patients With Stroke:
Pathophysiology and Management. Circulation. 2008;118(2):176-87.
55. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et
al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an
updated systematic review and meta-analysis. Lancet. 2012;379(9834):2364-
72.
56. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time
to treatment with intravenous alteplase and outcome in stroke: an updated
pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet.
2010;375(9727):1695-703.
57. Muhammad S, Haasbach E, Kotchourko M, Strigli A, Krenz A, Ridder DA, et
al. Influenza Virus Infection Aggravates Stroke Outcome. Stroke.
2011;42(3):783-91.
58. Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR, the GISC, et al.
Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary
analysis of the GAIN International trial. European Journal of Neurology.
2004;11(1):49-53.
59. Vargas M, Horcajada JP, Obach V, Revilla M, Cervera Á, Torres F, et al.
Clinical Consequences of Infection in Patients With Acute Stroke: Is It Prime
Time for Further Antibiotic Trials? Stroke. 2006;37(2):461-5.
60. Cheng B, Forkert ND, Zavaglia M, Hilgetag CC, Golsari A, Siemonsen S, et
al. Influence of Stroke Infarct Location on Functional Outcome Measured by
the Modified Rankin Scale. Stroke. 2014;45(6):1695-702.
61. Jørgensen HS, Reith J, Pedersen PM, Nakayama H, Olsen TS. Body
temperature and outcome in stroke patients. The Lancet. 1996;348(9021):193.
62. Kammersgaard LP, Jørgensen HS, Rungby JA, Reith J, Nakayama H, Weber
UJ, et al. Admission Body Temperature Predicts Long-Term Mortality After
Acute Stroke: The Copenhagen Stroke Study. Stroke. 2002;33(7):1759-62.
 44

63. Wang Y, Lim LL-Y, Levi C, Heller RF, Fisher J. Influence of Admission Body
Temperature on Stroke Mortality. Stroke. 2000;31(2):404-9.
64. Nakayama H, Jørgensen HS, Raaschou HO, Olsen TS. The influence of age on
stroke outcome. The Copenhagen Stroke Study. Stroke. 1994;25(4):808-13.
65. Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, Wolfe CDA,
et al. Sex Differences in the Clinical Presentation, Resource Use, and 3-Month
Outcome of Acute Stroke in Europe: Data From a Multicenter Multinational
Hospital-Based Registry. Stroke. 2003;34(5):1114-9.
66. Glader E-L, Stegmayr B, Norrving B, Terént A, Hulter-Åsberg K, Wester P-O,
et al. Sex Differences in Management and Outcome After Stroke: A Swedish
National Perspective. Stroke. 2003;34(8):1970-5.
67. Wyller TB, Sødring KM, Sveen U, Ljunggren AE, Bautz-Holter E. Are there
gender differences in functional outcome after stroke? Clinical Rehabilitation.
1997;11(2):171-9.
68. Kapral MK, Fang J, Hill MD, Silver F, Richards J, Jaigobin C, et al. Sex
Differences in Stroke Care and Outcomes: Results From the Registry of the
Canadian Stroke Network. Stroke. 2005;36(4):809-14.

69. Courties G, Herisson F, Sager H, Heidt T, Ye Y, Ying W, et al. Ischemic Stroke

Activates Hematopoietic Bone Marrow Stem Cells. Circulation Research. 2014.
70. Buck BH, Liebeskind DS, Saver JL, Bang OY, Yun SW, Starkman S, et al.
Early neutrophilia is associated with volume of ischemic tissue in acute stroke.
Stroke. 2008;39(2):355-60.
71. Nakayama H, Jørgensen H, Raaschou H, Olsen T. The influence of age on
stroke outcome. The Copenhagen Stroke Study. Stroke. 1994;25(4):808-13.
72. Boehme AK, Siegler JE, Mullen MT, Albright KC, Lyerly MJ, Monlezun DJ,
et al. Racial and gender differences in stroke severity, outcomes, and treatment
in patients with acute ischemic stroke. Journal of stroke and cerebrovascular
diseases : the official journal of National Stroke Association. 2014;23(4):e255-
61.
73. Ye JK, Zhang JT, Kong Y, Xu T, Zou TT, Zhang YH, et al. [Relationship
between white blood cell count, neutrophils ratio and erythrocyte
 45

sedimentation rate and short clinical outcomes among patients with acute
ischemic stroke at hospital admission]. Zhonghua liu xing bing xue za zhi =
Zhonghua liuxingbingxue zazhi. 2012;33(9):956-60.
 46

Lampiran 1. Ethical Clearance

 47

Lampiran 2. Surat izin penelitian

 48

Lampiran 3. Informed consent

49
Lampiran 4. Spreadsheet data
No Usia Jenis HDL LDL Kolesterol Trigliserid GDS Jumlah Skor Nilai Klinis
Kelamin Leukosit NIHSS NIHSS
1 49 Male 53 131 198 75 155 8.6 2 Defisit Ringan
2 50 Male 35 117 187 84 86 13.9 4 Defisit Ringan
3 59 Male 39 163 255 118 274 6.1 5 Defisit Ringan
4 60 Male 36 71 148 80 181 7.5 3 Defisit Ringan
5 60 Male 33 135 220 265 109 7.9 2 Defisit Ringan
6 65 Male 22 101 131 107 128 10.3 3 Defisit Ringan
7 67 Male 75 129 155 75 152 6.2 1 Defisit Ringan
8 68 Male 41 108 193 97 116 8.9 3 Defisit Ringan
9 45 Male 43 118 150 100 73 11 11 Defisit Cukup Berat
10 51 Male 35 137 188 91 104 9 6 Defisit Cukup Berat
11 58 Male 38 127 182 76 187 19.6 8 Defisit Cukup Berat
12 70 Male 44 133 199 89 125 7.4 6 Defisit Cukup Berat
13 41 Female 40 99 162 125 175 8.1 3 Defisit Ringan
14 52 Female 36 121 200 101 102 7.9 1 Defisit Ringan
15 54 Female 61 162 238 59 101 6.3 1 Defisit Ringan
16 55 Female 43 195 280 151 171 10.3 1 Defisit Ringan
17 58 Female 75 257 308 182 112 7.9 2 Defisit Ringan
18 59 Female 40 90 153 148 76 8.5 1 Defisit Ringan
19 66 Female 42 150 234 110 97 8.9 2 Defisit Ringan
20 58 Female 21 131 165 91 178 10 14 Defisit Cukup Berat
21 69 Female 57 173 250 114 132 12.5 14 Defisit Cukup Berat

50
 51

Lampiran 5. Output SPSS

Analisis Univariat
Jenis Kelamin

Frequency Percent Valid Percent Cumulative

Percent

Wanita 9 42.9 42.9 42.9

Valid Pria 12 57.1 57.1 100.0

Total 21 100.0 100.0

Nilai Klinis NIHSS

Frequency Percent Valid Percent Cumulative

Percent

Defisit Ringan 15 71.4 71.4 71.4

Valid Defisit Cukup Berat 6 28.6 28.6 100.0

Total 21 100.0 100.0

Descriptives
Statistic Std. Error
Usia pasien Mean 57.81 1.747
Lower Bound 54.17
95% Confidence Interval for Mean
Upper Bound 61.45
5% Trimmed Mean 58.06
Median 58.00
Variance 64.062
Std. Deviation 8.004
Minimum 41
Maximum 70
Range 29
Interquartile Range 14
Skewness -.281 .501
Kurtosis -.497 .972
Kadar HDL Mean 43.29 3.079
Lower Bound 36.86
95% Confidence Interval for Mean
Upper Bound 49.71
5% Trimmed Mean 42.76
 52

Median 40.00
Variance 199.114
Std. Deviation 14.111
Minimum 21
Maximum 75
Range 54
Interquartile Range 13
Skewness .960 .501
Kurtosis .998 .972
Kadar LDL Mean 135.62 8.716
Lower Bound 117.44
95% Confidence Interval for Mean
Upper Bound 153.80
5% Trimmed Mean 132.58
Median 131.00
Variance 1595.448
Std. Deviation 39.943
Minimum 71
Maximum 257
Range 186
Interquartile Range 44
Skewness 1.387 .501
Kurtosis 3.348 .972
Kadar Kolesterol Mean 199.81 10.252
Lower Bound 178.42
95% Confidence Interval for Mean
Upper Bound 221.20
5% Trimmed Mean 197.65
Median 193.00
Variance 2207.362
Std. Deviation 46.983
Minimum 131
Maximum 308
Range 177
Interquartile Range 78
Skewness .689 .501
Kurtosis -.100 .972
Kadar Trigliserida Mean 111.33 9.989
Lower Bound 90.50
95% Confidence Interval for Mean
Upper Bound 132.17
5% Trimmed Mean 105.88
Median 100.00
 53

Variance 2095.333
Std. Deviation 45.775
Minimum 59
Maximum 265
Range 206
Interquartile Range 40
Skewness 2.148 .501
Kurtosis 5.746 .972
Kadar GDS Mean 134.95 10.428
Lower Bound 113.20
95% Confidence Interval for Mean
Upper Bound 156.71
5% Trimmed Mean 130.89
Median 125.00
Variance 2283.748
Std. Deviation 47.789
Minimum 73
Maximum 274
Range 201
Interquartile Range 72
Skewness 1.202 .501
Kurtosis 2.093 .972
Jumlah Leukosit Mean 9.371 .6678
Lower Bound 7.978
95% Confidence Interval for Mean
Upper Bound 10.765
5% Trimmed Mean 9.000
Median 8.600
Variance 9.366
Std. Deviation 3.0604
Minimum 6.1
Maximum 19.6
Range 13.5
Interquartile Range 2.6
Skewness 2.076 .501
Kurtosis 5.593 .972
Skor NIHSS Mean 4.43 .893
Lower Bound 2.57
95% Confidence Interval for Mean
Upper Bound 6.29
5% Trimmed Mean 4.09
Median 3.00
Variance 16.757
 54

Std. Deviation 4.094

Minimum 1
Maximum 14
Range 13
Interquartile Range 5
Skewness 1.467 .501
Kurtosis 1.223 .972

Tests of Normality

Kolmogorov-Smirnova Shapiro-Wilk

Statistic df Sig. Statistic df Sig.

Usia pasien .129 21 .200* .965 21 .612

Kadar HDL .242 21 .002 .888 21 .021
Kadar LDL .200 21 .027 .903 21 .040
Kadar Kolesterol .165 21 .139 .948 21 .317
Kadar Trigliserida .204 21 .023 .795 21 .001
Kadar GDS .144 21 .200* .904 21 .043
Jumlah Leukosit .215 21 .012 .806 21 .001
Skor NIHSS .255 21 .001 .783 21 .000

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Analisis Bivariat

T-Test

Group Statistics

gender pasien N Mean Std. Deviation Std. Error Mean

Pria 12 4.50 2.876 .830

Skor NIHSS
Wanita 9 4.33 5.523 1.841
 Independent Samples Test

Levene's Test for Equality of t-test for Equality of Means

Variances

F Sig. t df Sig. (2- Mean Std. Error 95% Confidence Interval

tailed) Difference Difference of the Difference

Lower Upper

Equal variances 3.766 .067 1.218 19 .238 .57608 .47308 -.41409 1.56625
Skor assumed
NIHSS Equal variances not 1.101 10.446 .295 .57608 .52307 -.58268 1.73484
assumed

Correlations

Skor Jumlah Usia pasien Kadar Kadar Kadar LDL Kadar Kadar
NIHSS Leukosit GDS HDL Trigliserid Kolesterol

Pearson 1 .460* .066 .190 -.291 -.045 -.149 -.191

Correlation
Skor NIHSS
Sig. (2-tailed) .036 .775 .411 .200 .847 .520 .408

N 21 21 21 21 21 21 21 21
Pearson .460* 1 -.101 -.104 -.315 -.056 -.072 -.131
Correlation
Jumlah Leukosit
Sig. (2-tailed) .036 .663 .652 .164 .809 .756 .572
N 21 21 21 21 21 21 21 21

55
 Pearson .066 -.101 1 .072 .104 .097 .042 .120
Correlation
Usia pasien
Sig. (2-tailed) .775 .663 .758 .653 .676 .857 .603
N 21 21 21 21 21 21 21 21
Pearson .190 -.104 .072 1 -.093 .063 -.099 .110
Correlation
Kadar GDS
Sig. (2-tailed) .411 .652 .758 .687 .785 .669 .635
N 21 21 21 21 21 21 21 21
Pearson -.291 -.315 .104 -.093 1 .530* -.080 .472*
Correlation
Kadar HDL
Sig. (2-tailed) .200 .164 .653 .687 .013 .730 .031
N 21 21 21 21 21 21 21 21
Pearson -.045 -.056 .097 .063 .530* 1 .301 .902**
Correlation
Kadar LDL
Sig. (2-tailed) .847 .809 .676 .785 .013 .184 .000
N 21 21 21 21 21 21 21 21
Pearson -.149 -.072 .042 -.099 -.080 .301 1 .380
Correlation
Kadar Trigliserid
Sig. (2-tailed) .520 .756 .857 .669 .730 .184 .090
N 21 21 21 21 21 21 21 21
Pearson -.191 -.131 .120 .110 .472* .902** .380 1

Kadar Correlation

Kolesterol Sig. (2-tailed) .408 .572 .603 .635 .031 .000 .090
N 21 21 21 21 21 21 21 21

56
57
 57

Analisis Multivariat

Logistic Regression

Block 0: Beginning Block

Classification Tablea,b

Observed Predicted

Nilai Klinis NIHSS Percentage

.00 1.00 Correct

.00 15 0 100.0
Nilai Klinis NIHSS
Step 0 1.00 6 0 .0

Overall Percentage 71.4

a. Constant is included in the model.

b. The cut value is .500

Variables in the Equation

B S.E. Wald df Sig. Exp(B)

Step 0 Constant -.916 .483 3.598 1 .058 .400

Variables not in the Equation

Score df Sig.

VAR00002 .420 1 .517

Variables
Step 0 VAR00003 4.295 1 .038

Overall Statistics 4.308 2 .116

 58

Block 1: Method = Backward Stepwise (Likelihood Ratio)

Omnibus Tests of Model Coefficients

Chi-square df Sig.

Step 4.575 2 .102

Step 1 Block 4.575 2 .102

Model 4.575 2 .102

Step -.012 1 .912

Step 2a Block 4.562 1 .033

Model 4.562 1 .033

a. A negative Chi-squares value indicates that the Chi-

squares value has decreased from the previous step.

Model Summary

Step -2 Log likelihood Cox & Snell R Nagelkerke R

Square Square

1 20.553a .196 .281

2 20.565a .195 .280

a. Estimation terminated at iteration number 5 because

parameter estimates changed by less than .001.

Classification Tablea

Observed Predicted

Nilai Klinis NIHSS Percentage

.00 1.00 Correct

.00 12 3 80.0
Nilai Klinis NIHSS
Step 1 1.00 3 3 50.0

Overall Percentage 71.4

.00 10 5 66.7
Nilai Klinis NIHSS
Step 2 1.00 1 5 83.3

Overall Percentage 71.4

a. The cut value is .500

 59

Variables in the Equation

B S.E. Wald df Sig. Exp(B)

VAR00002 -.135 1.224 .012 1 .912 .873

Step 1a VAR00003 2.345 1.285 3.329 1 .068 10.434

Constant -2.291 1.054 4.727 1 .030 .101

VAR00003 2.303 1.225 3.535 1 .060 10.000
Step 2a
Constant -2.303 1.049 4.820 1 .028 .100

a. Variable(s) entered on step 1: VAR00002, VAR00003.

Model if Term Removed

Variable Model Log Change in -2 df Sig. of the

Likelihood Log Likelihood Change

VAR00002 -10.282 .012 1 .912

Step 1
VAR00003 -12.362 4.172 1 .041
Step 2 VAR00003 -12.564 4.562 1 .033

Variables not in the Equation

Score df Sig.

Variables VAR00002 .012 1 .912

Step 2a
Overall Statistics .012 1 .912

a. Variable(s) removed on step 2: VAR00002.

 60

Lampiran 6. Kuesioner penelitian

61
62
 63

Lampiran 7. Dokumentasi
 64

Lampiran 8. Biodata mahasiswa

Identitas
Nama : Yoshua Kevin Poonatajaya
NIM : 22010111120012
Tempat, tanggal lahir : Pati, 2 Oktober 1993
Jenis kelamin : Laki-laki
Alamat : Jl. Kolonel Sunandar 38 Pati
Nomor HP : 081225119904
e-mail : [email protected]

Riwayat Pendidikan Formal

SD : SD Kr. Aletheia Surabaya (Lulus tahun 2005)
SMP : SMP K Keluarga Pati (Lulus tahun 2008)
SMA : SMA N 1 Pati (Lulus tahun 2011)
FK UNDIP : masuk tahun 2011